Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

common-default.jpeg

Terms / Notices

Cookies

Privacy Policy

Reporting Hotline

Attorney Advertising

Alumni

  Linkedin

MoFo LinkedIN

  Facebook

MoFo Facebook

YouTube

MoFo Youtube

Morrison Foerster - Footer

The Pharmaceutical Compliance Forum's 2024 Annual Members Meeting

You have not solved the recaptcha challenge yet or session expired, try again.

Email Disclaimer

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

MoFo partner Adam Braverman will moderate a panel titled "Precision Medicines: 'The Right Drug for the Right Patient at the Right Time' - What Every Compliance Professional Should Know" at the Pharmaceutical Compliance Forum 2024 Annual Members Meeting on March 15, from 10:45 - 11:30 a.m. EST, in New York.

MoFo partner Adam Braverman will moderate a panel titled "Precision Medicines: 'The Right Drug for the Right Patient at the Right Time' - What Every Compliance Professional Should Know" at the Pharmaceutical Compliance Forum 2024 Annual Members Meeting on March 15, from 10:45 - 11:30 a.m. EST, in New York. Adam will lead a conversation on the complex ethical and regulatory considerations pharmaceutical companies must navigate to ensure patient safety, data privacy, and ethical conduct due to the increased focus on gene therapy and Precision Medicine. To learn more about the Pharmaceutical Compliance Forum, visit the <a href="https://www.pharmacomplianceforum.org/" target="_blank">event website</a>.<hr>

Sign Up

Adam L. Braverman is a partner in Morrison Foerster’s Investigations + White Collar Defense and Commercial Litigation + Trial Groups. Adam formerly served as an Associate Deputy Attorney General for the U.S. Department of Justice (DOJ) and as the U.S. Attorney for the Southern District of California.Adam represents companies and their executives in internal and government investigations, white collar criminal defense matters, and parallel civil litigation related to allegations of bribery, government procurement fraud, COVID-19 and CARES Act fraud, and anti-money laundering violations. He has particular experience representing clients in the government contracting, healthcare, life sciences, and professional sports sectors, including in internal and government-facing investigations related to the False Claims Act (FCA) and Anti-Kickback Statute (AKS), procurement fraud, bribery, national security, and disclosure obligations related to promoting foreign interests, among other issues. Adam also designs compliance policies on behalf of corporate clients and conducts trainings to ensure best practices in light of recent revisions to DOJ’s Evaluation of Corporate Compliance Programs and Corporate Criminal Enforcement Policies.Additionally, Adam advises on all aspects of complex commercial litigation in federal and state trial and appellate courts and in arbitration. He has represented clients in actions involving breach of contract and a wide array of complex commercial disputes.Before joining MoFo, Adam spent 13 years at DOJ, where he served in senior-level leadership positions in multiple administrations. As an Associate Deputy Attorney General, he advised the Deputy Attorney General on litigation and policy matters and was designated to coordinate DOJ’s efforts to investigate and prosecute fraud in connection with COVID-19 and CARES Act relief funds. During his tenure, he worked closely with all of DOJ’s law enforcement agencies, other federal agencies, INTERPOL, and the Organized Crime Drug Enforcement Task Force, as well as state and local law enforcement associations.Adam also served as U.S. Attorney for the Southern District of California, where he managed one of the largest and busiest U.S. Attorney’s Offices in the country, comprised of nearly 300 employees. In this role, Adam was responsible for enforcing all violations of federal law in the District and defending the nation in all civil lawsuits. Prior to becoming U.S. Attorney, Adam was an Assistant U.S. Attorney and Deputy Chief, leading complex investigations and prosecutions of large-scale international criminal organizations. Prior to joining the government, Adam was an associate at a leading global law firm, where he dedicated his practice to civil litigation, white collar criminal cases, and internal investigations.Adam received his J.D. from the George Washington University School of Law and his B.A., cum laude, from the George Washington University.<h4>Representative Experience</h4><ul><li>A major U.S. defense contractor in an FCA matter involving allegations of fraudulent billing and workplace misconduct by a former employee.</li><li>A small U.S. defense contractor in an FCA matter involving allegations of fraudulent billing and misrepresentations on grant applications.</li><li>An international defense contractor in a DOJ criminal investigation of allegations of bribery, wire fraud, and money laundering, as well as a civil investigation involving the FCA and allegations of fraudulent billing.</li><li>A major U.S. defense contractor in an internal investigation involving allegations of U.S. sanctions violations.</li><li>A healthcare organization in an FCA matter involving kickback allegations.</li><li>A medical device company in an internal investigation involving FCA kickback allegations.</li><li>Private equity firms in an FCA matter involving allegations of fraudulent billing.</li><li>An individual investigated by DOJ for alleged violations of International Traffic in Arms Regulations.</li><li>A public company in a Securities Exchange Act Section 14(a) challenge to a proxy statement alleging material omissions. </li><li>A professional sports team in a government investigation.</li><li>A property management company in a class action matter.</li><li>Corporate clients in undertaking compliance risk assessments and providing related counseling.</li></ul>

The Pharmaceutical Compliance Forum's 2024 Annual Members Meeting

15 Mar 2024 10:45 AM - 11:30 AM EDT